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Figure 1. Schematic model of  the FA-BRCA pathway. Upon ICL 
formation, the FA core complex monoubiquitinates FANCD2 
and FANCI. Upon monoubiquitination FANCD2 and FANCI 
localize to sites of  DNA damage where they interact with 
known DNA repair proteins.   
Fanconi anemia (FA) is a rare X-linked and autosomal disease 
characterized by bone marrow failure, congenital defects, and 
increased cancer susceptibility. FA is caused by mutations in 
any 1 of  16 genes. The protein products of  these genes work 
together in the FA-BRCA DNA damage response pathway to 
repair DNA interstrand crosslinks (ICLs). The FA-BRCA 
pathway is a critical tumor suppressor pathway.     
Background   
Figure 2. Comparison of  SCF E2/E3 and the FA-BRCA E2/E3 
ubiquitin ligase complexes. The SCF (for Skp1-Cul1-F-box 
protein) E3 ubiquitin ligase (A) is a large complex made up of  
the RBX1 E3 ubiquitin ligase, UBC E2 ubiquitin-conjugating 
enzyme, and the F-box protein which recognizes the substrate.  
Here, we propose a similar model for the ubiquitination of  
FANCD2 by the FA core complex (B), where FANCL is the E3 
ligase, UBE2T is the E2 ubiquitin-conjugating enzyme, and 
FANCE is the substrate (FANCD2) recognition protein.   
Figure 3. Generation of  overlapping fragments of  FANCD2.  
Four FANCD2 fragments were generated, each with a N-
terminal V5 epitope tag. The four fragments are based on the 
four solenoids of  FANCD2, designated S1-S4. 
Figure 4. Expression of  pcDNA3.1-V5-FANCD2 Fragments. 
COS7 cells were transfected with pcDNA3.1-V5-FANCD2 
fragments or no DNA (ND). Cells were harvested and lysed in 
2% SDS lysis buffer, and analyzed via Western blotting using 
anti-V5 and anti-tubulin antibodies.   
Figure 5. Expression of  FLAG-FANCE. A FLAG-tagged FANCE 
construct was also obtained. COS7 cells were transfected with 
pEAK8-FLAG-FANCE or no DNA (ND). Cells were harvested 
and lysed in 2% SDS lysis buffer, and analyzed via Western 
blotting using anti-FLAG and anti-tubulin antibodies.   
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Figure 7. Co-Immunoprecipitation of  V5-FANCD2 and HA-
FANCL.  A co-IP was performed to determine if  FANCD2 and 
FANCL interact. COS7 cells were transfected with no DNA 
(ND; lanes 3 and 7), pcDNA3.1-V5-FANCD2 (V5-D2; lanes 1 and 
5), pLenti6.2-HA-FANCL (HA-L; lanes 2 and 6), or both (V5-D2 + 
HA-L; lanes 4 and 8). Samples were lysed in low stringency 
buffer and immune complexes isolated with anti-V5 agarose.  
Samples were eluted and analyzed using Western blotting with 
anti-HA and anti-FANCD2 antibodies. 
Conclusions  
We have successfully generated mammalian expression 
constructs for four overlapping V5-tagged FANCD2 fragments 
and HA-tagged FANCL. We have also successfully optimized 
conditions for their ectopic expression in COS7 cells and also 
optimized the FLAG-tagged FANCE construct. In addition, we 
have begun to perform co-IP experiments to determine the 
specific regions of  FANCD2 to which FANCL and FANCE bind. 
Mapping these sites of  interaction will generate important 
mechanistic insight into the regulation of  this critical tumor 
suppressor pathway. 
Figure 6. Expression of  pLenti6.2 HA-FANCL.  COS7 cells were 
transfected with pLenti6.2-HA-FANCL, a FLAG/HA HPV16 
control, or no DNA (ND).  Cells were harvested and lysed in 2% 
SDS lysis buffer and analyzed via Western blotting using anti-
HA and anti-tubulin antibodies.      
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